|
|
【DPHARMA 7148 交流专区】（前名 CCMDBIO）
[复制链接]
|
|
|
发表于 21-3-2020 05:11 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 20-4-2020 08:18 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
31 Dec 2019 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2019 | 31 Dec 2018 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 137,755 | 115,634 | 576,462 | 498,722 | | 2 | Profit/(loss) before tax | 13,939 | 17,658 | 70,809 | 59,666 | | 3 | Profit/(loss) for the period | 12,033 | 14,369 | 55,273 | 47,641 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 12,033 | 14,369 | 55,273 | 47,641 | | 5 | Basic earnings/(loss) per share (Subunit) | 1.76 | 2.17 | 8.25 | 7.26 | | 6 | Proposed/Declared dividend per share (Subunit) | 5.00 | 4.00 | 6.00 | 5.50 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.7700 | 0.7300
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 20-4-2020 08:20 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 7-6-2020 07:51 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
31 Mar 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31 Mar 2020 | 31 Mar 2019 | 31 Mar 2020 | 31 Mar 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 158,713 | 150,386 | 158,713 | 150,386 | | 2 | Profit/(loss) before tax | 17,727 | 18,786 | 17,727 | 18,786 | | 3 | Profit/(loss) for the period | 13,561 | 14,465 | 13,561 | 14,465 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 13,561 | 14,465 | 13,561 | 14,465 | | 5 | Basic earnings/(loss) per share (Subunit) | 1.98 | 2.19 | 1.98 | 2.19 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.7900 | 0.7700
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 7-6-2020 07:54 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 9-6-2020 08:29 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | SUPPLY OF HUMAN INSULIN FORMULATIONS (HEREINAFTER REFERRED TO AS "PRODUCTS") UNDER MINISTRY OF HEALTH'S (MOH) OFF-TAKE AGREEMENT PROGRAM | We refer to our announcements dated 25 January 2017, 26 January 2017, 22 August 2017 and 2 December 2019 on the above.
Duopharma Biotech Berhad (“Duopharma Biotech” or the “Company”) is pleased to announce that the Government of Malaysia (“Government”), Biocon Sdn. Bhd. (“Biocon”) and Duopharma Marketing Sdn. Bhd. (formerly known as CCM Pharmaceuticals Sdn. Bhd.) (“DMktg”) (a wholly-owned subsidiary of the Company) had on 20 May 2020 entered into a Supplementary Agreement to formalise the amendments to the Agreement for the Supply and Delivery of Human Insulin Products (hereinafter referred to as “Agreement”) between the Government, Biocon and DMktg. The amendments include an extension of the contract period under the Agreement by one (1) year effective from 2 December 2019 until 1 December 2020 with an additional contract value of RM91,060,000.00. Pursuant to the additional contract value of RM91,060,000.00, the total contract value has been increased from RM300,040,500.00 under the original Agreement to RM391,100,500.00.
The Agreement and the Supplementary Agreement for the supply of the Products are in the ordinary course of business of the Duopharma Biotech Group.
This announcement is dated 21 May 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 23-8-2020 08:01 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | LISTING OF SCM LIFESCIENCE CO., LTD. (A COMPANY INCORPORATED IN THE REPUBLIC OF KOREA) ON KOSDAQ | The Board of Directors of Duopharma Biotech Berhad (“Duopharma Biotech” or the “Company”) wishes to announce that SCM Lifescience Co., Ltd. (Korean Company No: 120111-0715352) (hereinafter referred to as “SCM Lifescience”), an investee company of Duopharma Biotech has been listed on KOSDAQ (Korean Securities Dealers Automated Quotations) which is a trading board of Korea Exchange (“KRX”) in South Korea on 17 June 2020. SCM Lifescience is a corporation duly organised and existing under the laws of Korea, and is a biotechnology company focusing on cell-based therapy / stem cell products.
This announcement is dated 17 June 2020.
Please refer attachment below. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3059330
|
|
|
|
|
|
|
|
|
|
|
|
发表于 23-8-2020 08:01 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 25-8-2020 07:12 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | LISTING OF SCM LIFESCIENCE CO., LTD. (A COMPANY INCORPORATED IN THE REPUBLIC OF KOREA) ON KOSDAQ | Reference is made to Duopharma Biotech Berhad’s (“Duopharma Biotech” or the “Company”) earlier announcement dated 17 June 2020 (“Announcement”). All abbreviations and definitions used herein shall, unless expressly stated otherwise or where the context requires otherwise, have the same meaning as the words and expressions defined in the Announcement.
The Company wishes to announce that following the listing of SCM Lifescience Co. Ltd.’s shares on KOSDAQ, Duopharma Biotech has at to date sold a total of 218,688 SCM Lifescience shares via on-market trading on KOSDAQ at a total aggregated selling price of KRW6,993,577,013.
This announcement is dated 18 June 2020.
Please refer attachment below. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3060077
|
|
|
|
|
|
|
|
|
|
|
|
发表于 9-9-2020 09:47 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 12-9-2020 09:13 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 11-10-2020 07:53 AM
|
显示全部楼层
Entitlement subject | Final Dividend (with Dividend Re-Investment Plan) | Entitlement description | Final dividend of RM0.05 per ordinary share | Ex-Date | 13 Jul 2020 | Entitlement date | 14 Jul 2020 | Entitlement time | 5:00 PM | Financial Year End | 31 Dec 2019 | Share transfer book & register of members will be | to closed from (both dates inclusive) for the purpose of determining the entitlement | Payment Date | 12 Aug 2020 | a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers | 14 Jul 2020 | b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit |
| | c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange. | Number of new shares/securities issued (units)
(If applicable) |
| | Entitlement indicator | Currency | Entitlement in Currency | Malaysian Ringgit (MYR) 0.0500 | Options Available to Shareholders | Cash or Securities |
| Cash |
| Cash^ Entitlement |
| 1 | Tax Indicator | Tax Exempt / Non-taxable | Currency | Malaysian Ringgit (MYR) | Amount | 0.0500 |
| or Securities |
| Re-invest Cash Entitlement into Securities | Entitlement | Malaysian Ringgit (MYR) 0.0500 | Company Name | DUOPHARMA BIOTECH BERHAD | Issue Price per Unit | Malaysian Ringgit (MYR) 1.4100 | Deadline To Respond | 30 Jul 2020 05:00 PM | Securities Crediting Date | 12 Aug 2020 | Available/Listing Date | 13 Aug 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 13-10-2020 02:41 PM
|
显示全部楼层
本帖最后由 icy97 于 14-12-2020 08:53 AM 编辑
谢谢楼主分享
|
|
|
|
|
|
|
|
|
|
|
|
发表于 16-10-2020 02:57 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 4-12-2020 07:33 AM
|
显示全部楼层
Type | Announcement | Subject | NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
OTHER ISSUE OF SECURITIES | Description | DUOPHARMA BIOTECH BERHAD ("DUOPHARMA BIOTECH" OR THE "COMPANY")DIVIDEND REINVESTMENT PLAN ("DRP") | We refer to the announcements made on 13 February 2020, 19 June 2020, 24 June 2020, 30 June 2020 and 16 July 2020 in relation to the DRP (“Announcements”). For consistency purposes, the abbreviations used in this announcement are the same as those previously defined in the Announcements unless otherwise defined herein.
On behalf of the Board, Mercury Securities wishes to announce that based on the valid dividend reinvestment forms received by Tricor Investor & Issuing House Services Sdn Bhd, being the share registrar of the Company for the DRP, Duopharma Biotech will be issuing 21,643,754 new Duopharma Biotech Shares (“New Shares”) pursuant to the DRP. The New Shares to be issued represent approximately 89.20% of the total number of 24,264,528 New Shares that would have been issued pursuant to the DRP had all the entitled shareholders of Duopharma Biotech elected to reinvest their respective Electable Portions of their cash dividend into New Shares.
Barring any unforeseen circumstances, the said New Shares pursuant to the DRP are expected to be listed on the Main Market of Bursa Securities on 13 August 2020.
This announcement is dated 7 August 2020. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 10-12-2020 05:34 AM
|
显示全部楼层
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Others | Details of corporate proposal | Dividend Reinvestment Plan applicable to the final single-tier dividend of RM0.05 per ordinary share in Duopharma Biotech Berhad for the financial year ended 31 December 2019 | No. of shares issued under this corporate proposal | 21,643,754 | Issue price per share ($$) | Malaysian Ringgit (MYR) 1.4100 | Par Value($$) (if applicable) |
| | Latest issued share capital after the above corporate proposal in the following | Units | 706,026,918 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 404,922,707.640 | Listing Date | 13 Aug 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 11-12-2020 05:46 AM
|
显示全部楼层
本帖最后由 icy97 于 12-12-2020 08:40 AM 编辑
SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Jun 2020 | 30 Jun 2019 | 30 Jun 2020 | 30 Jun 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 143,331 | 145,466 | 302,044 | 295,852 | | 2 | Profit/(loss) before tax | 19,391 | 18,316 | 37,118 | 37,102 | | 3 | Profit/(loss) for the period | 14,729 | 13,916 | 28,290 | 28,381 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 14,729 | 13,916 | 28,290 | 28,381 | | 5 | Basic earnings/(loss) per share (Subunit) | 2.15 | 2.07 | 4.13 | 4.26 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.50 | 1.00 | 0.50 | 1.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.8500 | 0.7700
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 11-12-2020 05:46 AM
|
显示全部楼层
Entitlement subject | Interim Dividend | Entitlement description | Interim Single-Tier Dividend of 0.5 sen per ordinary share | Ex-Date | 28 Aug 2020 | Entitlement date | 01 Sep 2020 | Entitlement time | 5:00 PM | Financial Year End | 31 Dec 2020 | Period |
| | Share transfer book & register of members will be | to closed from (both dates inclusive) for the purpose of determining the entitlement | Payment Date | 11 Sep 2020 | a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers | 01 Sep 2020 | b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit |
| | c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange. | Number of new shares/securities issued (units)
(If applicable) |
| | Entitlement indicator | Currency | Announced Currency | Malaysian Ringgit (MYR) | Disbursed Currency | Malaysian Ringgit (MYR) | Entitlement in Currency | Malaysian Ringgit (MYR) 0.0050 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 11-12-2020 05:47 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 13-12-2020 08:36 AM
|
显示全部楼层
本帖最后由 icy97 于 4-10-2021 09:30 AM 编辑
Particulars of substantial Securities HolderName | PERMODALAN NASIONAL BERHAD | Address | Tingkat 4, Balai PNB, 201-A, Jalan Tun Razak,
Kuala Lumpur
50400 Wilayah Persekutuan
Malaysia. | Company No. | 197801001190 (38218-X) | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | Ordinary Shares |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 13 Aug 2020 | 11,285,007 | Others | Direct Interest | Name of registered holder | PERMODALAN NASIONAL BERHAD | Address of registered holder | TINGKAT 4, BALAI PNB, 201-A, JALAN TUN RAZAK, 50400 KUALA LUMPUR. | Description of "Others" Type of Transaction | DRP |
Circumstances by reason of which change has occurred | Elected to reinvest in 11,285,007 new shares pursuant to the Dividend Reinvestment Plan ("DRP"). | Nature of interest | Direct Interest | Direct (units) | 329,522,228 | Direct (%) | 46.673 | Indirect/deemed interest (units) |
| | Indirect/deemed interest (%) |
| | Total no of securities after change | 329,522,228 | Date of notice | 13 Aug 2020 | Date notice received by Listed Issuer | 17 Aug 2020 |
Name | EMPLOYEES PROVIDENT FUND BOARD | Address | TINGKAT 19, BANGUNAN KWSP, JALAN RAJA LAUT
KUALA LUMPUR
50350 Wilayah Persekutuan
Malaysia. | Company No. | EPF ACT 1991 | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | Ordinary Shares |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 13 Aug 2020 | 1,504,512 | Others | Direct Interest | Name of registered holder | Citigroup Nominees (Tempatan) Sdn. Bhd. | Address of registered holder | Level 42, Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur. | Description of "Others" Type of Transaction | DRP | | 2 | 13 Aug 2020 | 116,570 | Others | Direct Interest | Name of registered holder | Citigroup Nominees (Tempatan) Sdn. Bhd. | Address of registered holder | Level 42, Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur. | Description of "Others" Type of Transaction | DRP | | 3 | 13 Aug 2020 | 557,415 | Others | Direct Interest | Name of registered holder | Citigroup Nominees (Tempatan) Sdn. Bhd. | Address of registered holder | Level 42, Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur. | Description of "Others" Type of Transaction | DRP | | 4 | 13 Aug 2020 | 58,039 | Others | Direct Interest | Name of registered holder | Citigroup Nominees (Tempatan) Sdn. Bhd. | Address of registered holder | Level 42, Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur. | Description of "Others" Type of Transaction | DRP | | 5 | 13 Aug 2020 | 37,652 | Others | Direct Interest | Name of registered holder | Citigroup Nominees (Tempatan) Sdn. Bhd. | Address of registered holder | Level 42, Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur. | Description of "Others" Type of Transaction | DRP |
Circumstances by reason of which change has occurred | (1) CITIGROUP NOMINEES (TEMPATAN) SDN BHD- Employees Provident Fund Board(Elected to reinvest in 1,504,512 new shares pursuant to the Dividend Reinvestment Plan ("DRP")).(2) CITIGROUP NOMINEES (TEMPATAN) SDN BHD- Employees Provident Fund Board (AM INV)(Elected to reinvest in 116,570 new shares pursuant to the DRP).(3) CITIGROUP NOMINEES (TEMPATAN) SDN BHD- Employees Provident Fund Board (CIMB PRI) (Elected to reinvest in 557,415 new shares pursuant to the DRP).(4) CITIGROUP NOMINEES (TEMPATAN) SDN BHD- Employees Provident Fund Board (ABERISLAMIC) IC.(Elected to reinvest in 58,039 new shares pursuant to the DRP).(5) CITIGROUP NOMINEES (TEMPATAN) SDN BHD- Employees Provident Fund Board (NIAM EQ) IC.(Elected to reinvest in 37,652 new shares pursuant to the DRP). | Nature of interest | Indirect Interest | Direct (units) |
| | Direct (%) |
| | Indirect/deemed interest (units) | 53,143,077 | Indirect/deemed interest (%) | 7.527 | Total no of securities after change | 53,143,077 | Date of notice | 14 Aug 2020 | Date notice received by Listed Issuer | 18 Aug 2020 |
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2020 |
| INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2020 | 30 Sep 2019 | 30 Sep 2020 | 30 Sep 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 133,772 | 142,855 | 435,816 | 438,707 | | 2 | Profit/(loss) before tax | 18,568 | 19,768 | 55,686 | 56,870 | | 3 | Profit/(loss) for the period | 14,127 | 14,859 | 42,417 | 43,240 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 14,127 | 14,859 | 42,417 | 43,240 | | 5 | Basic earnings/(loss) per share (Subunit) | 2.03 | 2.20 | 6.16 | 6.49 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.50 | 1.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.8400 | 0.7700
|
Type | Announcement | Subject | OTHERS | Description | Duopharma Biotech Posts Another Strong Quarter Registering PBT of RM18.57 million | We attach herewith a copy of press release dated 12 November 2020.
This announcement is dated 12 November 2020.
Please refer attachment below. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3104505
Type | Announcement | Subject | OTHERS | Description | 1. TERM SHEET BETWEEN THE JOINT-STOCK COMPANY "MANAGEMENT COMPANY OF RUSSIAN DIRECT INVESTMENT FUND" AND DUOPHARMA (M) SENDIRIAN BERHAD ("DMSB"), A WHOLLY-OWNED SUBSIDIARY OF DUOPHARMA BIOTECH, FOR THE DISTRIBUTION OF THE 'SPUTNIK V' VACCINE ("VACCINE") IN MALAYSIA; AND2. TERM SHEET BETWEEN THE GOVERNMENT OF MALAYSIA AND DMSB, FOR THE SUPPLY OF THE VACCINE TO THE GOVERNMENT. | The Board of Directors (the “Board”) of Duopharma Biotech Berhad (”Duopharma Biotech” or the “Company”) wishes to announce that Duopharma (M) Sendirian Berhad (“DMSB”), a wholly-owned subsidiary of the Company, had on 26 January 2021 entered into the following term sheets:
(i) a term sheet with the Joint-Stock Company "Management Company of Russian Direct Investment Fund" for the distribution of the finished form of the “Sputnik V” adenovirus vector vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology for SARS-Cov-2 (COVID-19) (the “Vaccine”) in Malaysia; and
(ii) a term sheet with the Government of Malaysia, represented by the Ministry of Health, Malaysia (the “Government”), for the supply by DMSB to the Government of the finished form of the Vaccine.
Please refer to the attachment for details of the announcement.
This announcement is dated 26 January 2021. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3124553
Type | Announcement | Subject | OTHERS | Description | DUOPHARMA BIOTECH TO SUPPLY 6.4 MILLION DOSES OF THE RUSSIAN COVID-19 VACCINE TO THE NATION | We attach herewith a copy of press release dated 26 January 2021.
This announcement is dated 26 January 2021.
Please refer attachment below. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3124555
|
|
|
|
|
|
|
|
|
|
| |
本周最热论坛帖子
|
1594 
37
